# DESCRIPTION

## FIELD OF THE INVENTION

- relate to novel binding interactions

## BACKGROUND OF THE INVENTION

- describe S100A9 protein
- describe RAGE receptor

## SUMMARY OF THE INVENTION

- introduce novel binding interactions

## DESCRIPTION OF THE SEQUENCES MENTIONED HEREIN

- list sequence IDs

## DETAILED DESCRIPTION OF THE INVENTION

- introduce method for identifying therapeutic compounds
- describe use of S100A9 and ligand in method
- outline binding assays for identifying compounds
- describe characteristics of compounds to be selected
- outline preferred embodiments of method
- describe forms and variants of S100A9 and ligand
- outline post-translational modifications of S100A9 and ligand
- describe purification and production of S100A9 and ligand
- define homologues of sequences
- outline further testing of identified compounds

### Homologues

- define homology and its calculation
- describe use of BLAST algorithm for homology calculation
- outline conservative substitutions in homologous sequences

### Further Testing of the Identified Compound

- outline cell-based and animal model assays for further testing
- describe administration of compound to animal and determination of therapeutic efficacy

### The Antibody of the Invention

- describe antibody 43/8
- define epitope on S100A9
- specify antibody binding to S100A9
- describe antibody inhibition of S100A9 binding to TLR4 and/or RAGE
- specify antibody binding to monocytes
- describe antibody stimulation of TNFα production
- specify antibody recognition of unique epitope
- describe antibody production by immunization of S100A9 null mouse

### Administration

- formulate compounds into pharmaceutical composition
- specify routes of administration
- describe pharmaceutical carriers or diluents
- determine therapeutically effective non-toxic amount of substance

### Proteomic Screen

- describe proteomic screen for compounds binding S100A9 or RAGE

### The Biacore Assay

- describe Biacore assay system for screening compounds

### The Immobilization of RAGE to a Chip

- describe immobilization of RAGE to a chip using random amine coupling chemistry

### The Novel Interaction S100A9 and RAGE

- demonstrate S100A9 binding to RAGE
- determine optimal zinc ion concentration
- compare binding of S100A9 to RAGE with other S100 proteins
- show S100A9 binding to RAGE is modulated by compound A
- demonstrate S100A9 binding to immobilized TLR4
- show displacement of S100A9 binding to TLR4 by compound A
- analyze S100A9 surface expression on human monocytes
- describe in vitro assays for S100A9 binding compounds

## Materials and Methods

### Compound A

- synthesize compound A

### Biosensor Analysis

- describe SPR technology

### Immobilization of RAGE

- immobilize RAGE on sensor chip
- test activity of immobilized RAGE

### Immobilization of TLR4/MD-2 Complex

- immobilize TLR4/MD-2 on sensor chip

### Competition Assay

- describe competition assay format

### Evaluation of Binding Data

- evaluate binding data using BIAevaluation Software

### Purification of Splenic DCs and Human PBMCs

- purify splenic DCs and human PBMCs

### MLR Reactions

- perform MLR reactions

### Analysis of Cell Subsets by Flow Cytometry

- analyze cell subsets by flow cytometry

## Autoimmune Disease Models

- describe autoimmune disease models

### The Nonobese Diabetic (NOD) Mouse Model for Autoimmune Insulin-Dependent Diabetes Mellitus (IDDM)

- describe NOD mouse model

## Generation of Anti-S100A9 Monoclonal Antibody 43/8

- generate monoclonal antibody

### BIACORE™ Assays Demonstrates the Binding Ability of the Anti-S100A9 mAb 43/8

- demonstrate binding ability

### The Anti-S100A9 mAb 43/8 is Specific to Human S100A9

- demonstrate specificity
- analyze binding to various S100 proteins

### The Anti-S100A9 mAb 43/8 Blocks Binding of Human S100A9 to TLR4/MD-2

- demonstrate blocking ability
- calculate IC50 value

### The Anti-S100A9 Antibody Recognizes a Unique Epitope

- demonstrate unique epitope recognition

### The Anti-S100A9 mAb 43/8 Stimulates TNFα-Production in Peripheral Blood Mononuclear Cells

- demonstrate TNFα production stimulation

### The Anti-S100A9 mAb 43/8 Stimulates an NFκB Reporter Gene in LNCaP Cells

- demonstrate NFκB reporter gene stimulation

## Conclusion

- summarize antibody properties

### Compound A is an Efficient Modulator of S100A9 Binding to RAGE and TLR4

- demonstrate modulating ability

